These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 29427676

  • 1. In vitro susceptibility to ST-246 and Cidofovir corroborates the phylogenetic separation of Brazilian Vaccinia virus into two clades.
    Pires MA, Rodrigues NFS, de Oliveira DB, de Assis FL, Costa GB, Kroon EG, Mota BEF.
    Antiviral Res; 2018 Apr; 152():36-44. PubMed ID: 29427676
    [Abstract] [Full Text] [Related]

  • 2. Mutations in the E9L polymerase gene of cidofovir-resistant vaccinia virus strain WR are associated with the drug resistance phenotype.
    Kornbluth RS, Smee DF, Sidwell RW, Snarsky V, Evans DH, Hostetler KY.
    Antimicrob Agents Chemother; 2006 Dec; 50(12):4038-43. PubMed ID: 16982794
    [Abstract] [Full Text] [Related]

  • 3. ST-246 is a key antiviral to inhibit the viral F13L phospholipase, one of the essential proteins for orthopoxvirus wrapping.
    Duraffour S, Lorenzo MM, Zöller G, Topalis D, Grosenbach D, Hruby DE, Andrei G, Blasco R, Meyer H, Snoeck R.
    J Antimicrob Chemother; 2015 May; 70(5):1367-80. PubMed ID: 25630650
    [Abstract] [Full Text] [Related]

  • 4. Characterization of a new Vaccinia virus isolate reveals the C23L gene as a putative genetic marker for autochthonous Group 1 Brazilian Vaccinia virus.
    Assis FL, Almeida GM, Oliveira DB, Franco-Luiz AP, Campos RK, Guedes MI, Fonseca FG, Trindade GS, Drumond BP, Kroon EG, Abrahão JS.
    PLoS One; 2012 May; 7(11):e50413. PubMed ID: 23189200
    [Abstract] [Full Text] [Related]

  • 5. Specific targeting of the F13L protein by ST-246 affects orthopoxvirus production differently.
    Duraffour S, Vigne S, Vermeire K, Garcel A, Vanstreels E, Daelemans D, Yang G, Jordan R, Hruby DE, Crance JM, Garin D, Andrei G, Snoeck R.
    Antivir Ther; 2008 May; 13(8):977-90. PubMed ID: 19195323
    [Abstract] [Full Text] [Related]

  • 6. Mutations conferring resistance to viral DNA polymerase inhibitors in camelpox virus give different drug-susceptibility profiles in vaccinia virus.
    Duraffour S, Andrei G, Topalis D, Krečmerová M, Crance JM, Garin D, Snoeck R.
    J Virol; 2012 Jul; 86(13):7310-25. PubMed ID: 22532673
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Cutaneous infections of mice with vaccinia or cowpox viruses and efficacy of cidofovir.
    Quenelle DC, Collins DJ, Kern ER.
    Antiviral Res; 2004 Jul; 63(1):33-40. PubMed ID: 15196818
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Polycyclic N-benzamido imides with potent activity against vaccinia virus.
    Torres E, Duque MD, Camps P, Naesens L, Calvet T, Font-Bardia M, Vázquez S.
    ChemMedChem; 2010 Dec 03; 5(12):2072-8. PubMed ID: 20967819
    [Abstract] [Full Text] [Related]

  • 14. Assessing the variability of Brazilian Vaccinia virus isolates from a horse exanthematic lesion: coinfection with distinct viruses.
    Campos RK, Brum MC, Nogueira CE, Drumond BP, Alves PA, Siqueira-Lima L, Assis FL, Trindade GS, Bonjardim CA, Ferreira PC, Weiblen R, Flores EF, Kroon EG, Abrahão JS.
    Arch Virol; 2011 Feb 03; 156(2):275-83. PubMed ID: 21080203
    [Abstract] [Full Text] [Related]

  • 15. Serro 2 Virus Highlights the Fundamental Genomic and Biological Features of a Natural Vaccinia Virus Infecting Humans.
    Trindade GS, Emerson GL, Sammons S, Frace M, Govil D, Fernandes Mota BE, Abrahão JS, de Assis FL, Olsen-Rasmussen M, Goldsmith CS, Li Y, Carroll D, Guimarães da Fonseca F, Kroon E, Damon IK.
    Viruses; 2016 Dec 10; 8(12):. PubMed ID: 27973399
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge.
    Yang G, Pevear DC, Davies MH, Collett MS, Bailey T, Rippen S, Barone L, Burns C, Rhodes G, Tohan S, Huggins JW, Baker RO, Buller RL, Touchette E, Waller K, Schriewer J, Neyts J, DeClercq E, Jones K, Hruby D, Jordan R.
    J Virol; 2005 Oct 10; 79(20):13139-49. PubMed ID: 16189015
    [Abstract] [Full Text] [Related]

  • 18. Isolation and characterization of cidofovir resistant vaccinia viruses.
    Becker MN, Obraztsova M, Kern ER, Quenelle DC, Keith KA, Prichard MN, Luo M, Moyer RW.
    Virol J; 2008 May 14; 5():58. PubMed ID: 18479513
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.